Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Establishment and Characterization of Patient-Derived Non-Small Cell Lung Cancer Xenografts and Cell Cultures

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by National University Hospital, Singapore.
Recruitment status was  Recruiting
Information provided by:
National University Hospital, Singapore Identifier:
First received: May 24, 2010
Last updated: January 21, 2014
Last verified: January 2014
Xenografts and cell cultures provide sufficient material for analyses at the protein, RNA and DNA level. Patient derived NSCLC xenografts and cell lines are available but none however are Asian in origin. Given the emerging evidence to suggest inter-ethnic differences in NSCLC biology, new models of preclinical drug evaluation should be designed and validated using Asian tumors. Furthermore, such models will allow studies of biological mechanisms of sensitivity and/or resistance and also the study of dynamic regulations under standardized conditions in the Asian context.

Condition Intervention
Non Small Cell Lung Cancer
Procedure: Xenografts and cell cultures

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by National University Hospital, Singapore:

Study Start Date: September 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Non-Small Cell Lung Cancer Procedure: Xenografts and cell cultures


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The investigators for this protocol are clinicians and scientists in the departments of Cardiac/Thoracic and Vascular Surgery, Haematology and Oncology, Pathology, Radiation Oncology, Respiratory Medicine and the Cancer Sciences Institute of Singapore (CSIS) from NUH and NUS with major roles in their departments in the clinical management and/or research of lung cancer. Each will be providing access to clinical information and assisting in the collection and processing of samples, according to their resources and expertise.

Inclusion Criteria:

  • Patients aged 21 years and above.
  • Undergoing a surgical resection of tumor as part of clinical management

Exclusion Criteria:

  • Patient or legally acceptable representative unable to provide consent patient in the judgement of the study investigator, is medically unsuitable for this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01130571

Contact: Ross Andrew Soo, MBBS 65 3772 4624

National University Hospital Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS    65 6772 4624   
Principal Investigator: Ross Andrew Soo, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications: Identifier: NCT01130571     History of Changes
Other Study ID Numbers: NS03/05/09 
Study First Received: May 24, 2010
Last Updated: January 21, 2014
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on October 21, 2016